Charlesson, LLP

Oklahoma City, OK 73104

SBIR Award Summary

Total Number of Awards 29
Total Value of Awards $11.3MM
First Award Date 09/30/04
Most Recent Award Date 09/01/16

Key Personnel

Last Name Name Awards Contact
Feng Yan Feng 1
Moiseyev Gennadiy Moiseyev 2
Lu Kangmo Lu 5
Chen Danyang Chen 11
Farjo Rafal A Farjo 8
Wassel Ronald A Wassel 2
VANLANDINGHAM PHILLIP VANLANDINGHAM 1

29 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/01/16 - 08/31/17

? DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of vision loss in the United States. Although the anti-vascular endothelial growth factor (VEGF) drugs have shown impressive efficacies on wet age-related macular degeneration (AMD), they are only effective in approximatel...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/01/16 - 08/31/17

? DESCRIPTION (provided by applicant): This Small Business Innovation Research project aims to develop an innovative eye drop formulation for the treatment of diabetic retinopathy. The goal of this proposal is to develop substantial efficacy, safety, and pharmacokinetic data to support the clinical development of topical fenofibrate. We hypo...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 09/30/15 - 08/31/16

DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of vision loss in the United States. Although the anti-vascular endothelial growth factor (VEGF) drugs have shown impressive efficacies on wet age-related macular degeneration (AMD), they are only effective in approximately 50%...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 08/01/15 - 07/31/16

DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a common disease of the central retina and remains a leading cause of vision loss and blindness in elderly Americans. Currently, the standard of care for wet-AMD is intravitreal vascular endothelial growth factor (VEGF) inhibitors. However, these therapies are not alw...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-088
Budget: 04/01/14 - 03/31/15

PROJECT SUMMARY/ABSTRACT Age-related macular degeneration (AMD) is characterized by progressively decreased central vision and visual acuity and remains a leading cause of vision loss and blindness in aged Americans. Currently, the standard of care for AMD is intravitreal vascular endothelial growth factor (VEGF) inhibitors. Clinical studies ha...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 03/01/13 - 02/28/14

DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of vision loss in the United States. Unfortunately, there is no FDA-approved pharmacotherapy for DR. Current treatments in clinical practice and trails, such as laser photocoagulation, corticosteroids and anti-vascular endothel...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 02/01/13 - 01/31/14

DESCRIPTION (provided by applicant): The objective of this proposal is to finalize development of CLT-005, a novel small molecule inhibitor of Stat3, through the performance of studies required for the submission of an investigative new drug application with the US Food and Drug Administration (FDA). Activation of the Stat3 pathway in retinal...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-11-096
Budget: 05/01/12 - 04/30/13

DESCRIPTION (provided by applicant): Diabetic retinopathy (DR) is a common complication of diabetes and a leading cause of blindness. This sight-threatening condition has become a public health challenge in the US. Currently, there is no FDA- approved drug for DR. Laser photocoagulation has remained the gold standard for the treatment of DR over...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 02/01/12 - 01/31/13

DESCRIPTION (provided by applicant): The objective of this proposal is to finalize development of CLT-005, a novel small molecule inhibitor of Stat3, through the performance of studies required for the submission of an investigative new drug application with the US Food and Drug Administration (FDA). Activation of the Stat3 pathway in retinal...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 09/01/11 - 08/31/12

DESCRIPTION (provided by applicant): This Small Business Innovation project aims to develop an innovative eye drop formulation for the treatment of glaucoma and ocular hypertension. Charlesson has acquired from Danube Pharmaceuticals MSH-1001, a new small molecule compound (previously known as DNB-001 or KR- 31378). MSH-1001 is has both ocular h...

Load More